**Patient Name** MS. TERESIA MUGURE **Client Name** Walk-In Specimen Received 14-March-2019 WAWERU Specimen Type Wax Block **Client Code** Age/Sex 38/F **Collection Date** 14-March-2019 Ref. Doctor 011903140066 **Patient ID** Report Date 15-March-2019 Specimen ID MOLQ/IHC-11032019


### SURGICAL PATHOLOGY REPORT


### **Carcinoma of Left Breast**

#### **RESULTS**

# Programmed Death Ligand 1 (PD-L1)

Tumor Cells (TC) : Negative Tumor Infiltrating Lymphocytes (TILs) : Negative








Fig. 1 Fig. 2 Fig. 3

\*TC- Tumor Cells, TILs- Tumor Infiltrating Lymphocytes

### **SPECIMEN**

Carcinoma of Left Breast Received one paraffin block labelled as R-5037/18.

### **Immunohistochemical Staining**

Immunostaining for PD-L1 protein was done using Ventana Rabbit Anti-Human PD-L1/CD274 Monoclonal Antibody (Clone SP-263) on Ventana Autostainer. Positive PD-L1 staining/expression is defined as complete and/or partial, circumferential or linear plasma membrane staining at any intensity that can be differentiated from background and diffuse cytoplasmic staining.

Patient Name	MS. TERESIA MUGURE	Client Name	Walk-In	Specimen Received	14-March-2019
	WAWERU			Specimen Type	Wax Block
Age/Sex	38/F	Client Code		<b>Collection Date</b>	14-March-2019
Patient ID	011903140066	Ref. Doctor		Report Date	15-March-2019
Specimen ID	MOLQ/IHC-11032019			-	

# **Microscopic Findings:**

## Programmed Death Ligand 1 (PD-L1) Immunostaining in Tumor Cells (TC) (Fig.2)

#### **Membrane Staining**

Cells immunoreactive – Score 0 Intensity- Score 0

## **Cytoplasm Staining**

Cells immunoreactive – Score 0 Intensity- Score 0

**Total Score: 00** 

## Programmed Death Ligand 1 (PD-L1) Immunostaining in Tumor Infiltrating Lymphocytes (TILs) (Fig. 3)

#### **Membrane Staining**

Cells immunoreactive – 00%

Intensity- 0

### **Cytoplasm Staining**

Cells immunoreactive – 00% Intensity- 0

Gulshan Yadav, MD Head & Senior Consultant

**Pathologist** 



Tina Bhardwaj, MDS Consultant Pathologist

# Inference:

### **Immunoreactive Scoring System (IRS) Tumor Cells**

#### A) Percentage of Stained Cells:

Score 0: <1% Positive Cells Score 1: 1%-50% Positive Cells Score 2: >50% Positive Cells

### B) Staining Intensity:

Score 0: No immunostaining Score 1: Weak staining Score 2: Moderate staining Score 3: Strong staining

IRS=A+B Range: 0-5

#### **Interpretation:**

A total score of <2 - Negative A total score of  $\ge 2$  - Positive

Programmed Cell Death Ligand 1 (PD-L1) is a protein encoded by the CD274 gene. It is crucial in maintaining immune homeostasis. PD-L1 works by attaching to the T-Cell receptors called PD1 and B7.1 (both inactive T cells). PD-L1 is an important prognostic and theranostic biomarker in the study of several neoplasma. PD-L1 overexpression may facilitate tumor growth and metastasis, and has been observed in carcinomas of Lungs, Thymus, Bladder, Colon, Pancreas, Ovary, Kidney, Breast, Melanoma and Glioblastoma.

#### Reference

- 1. Rosai and Ackerman's Surgical Pathology.
- Modern Surgical Pathology.
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis Lihu Gu, Manman Chen, Dongyu Guo, Hepan Zhu, Wenchao Zhang PLOS ONE August 2017;12:8 14 Pages
- PD-L1 Expression in Triple-Negative Breast Cancer Elizabeth A. Mittendorf, Anne V. Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington Cancer Immunol Res 2(4) April 2014
- Clinical Significance Of PD1 And PDL1 In Human Breast Cancer Michal Uhercik Andrew J. Sanders, Sioned Owen Eleri L. Davies Anticancer Res August 2017 37 (8) 4249-4254
- Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics Ping Wei, Mulan Jin, Xiang Zhou, Xiumei Hu, Ying Wang Int J Clin Exp Pathol 2018;11:4 10 Pages

Report generated at MolQ Laboratory, Gurgaon